AbbVie’s $11B Apogee Acquisition Brings an Eczema Drug With an Edge
AbbVie is boosting its already strong presence in immunology with the acquisition of Apogee Therapeutics, a clinical-stage biotech whose most advanced drug candidate could bring advantages over several currently available atopic dermatitis medications, …